Fero Industries’ Growth Strategy (OTC:FROI)

Fero Industries, Inc (OTC:FROI) has announced their growth strategy publicly where they have disclose about Fero Industries first acquisition target which is Pyro Pharmaceuticals. The Company is said to be a boutique developmental stage pharmaceutical company which focuses on new class of antibiotics to fight drug resistant bacteria like MRSA. With this merger Fero Industries will not only acquire 11 potentially promising new patents but will also acquire the expert management and scientific advisers from Pyro Pharmaceuticals. Pyro currently has one issued and ten pending patents that protect a new class of antibiotics that are made to combat bacteria.

@@AdsenseRight@@ Fero Industries is planning to grow through acquisition strategy for 2010 and they have already begun the initial negotiations with Pyro Pharmaceuticals. Fero also intends to take advantage of Pyro’s acquisition by mixing Pyro’s world class management team and future acquisitions for the growth of the companies both horizontally and vertically with strategic and synergistic acquisition targets which will be announced when certain milestones are reached for this merger.

Another reason why Fero Industries have gone for the acquisition is because of Pyro’s management and board members who have extensively public company experience and because they have successfully handled acquisitions and joint ventures with various large companies. In the past Pyro has attracted impressive number of pharmaceutical companies like Merck, Glaxo, Abbott, Bristol-Myers Squibb and Cubist Pharmaceuticals and many others.